

SD-208

Catalog No: tcsc0895



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

627536-09-8

Formula:

$C_{17}H_{10}ClFN_6$

Pathway:

TGF-beta/Smad

Target:

TGF- β Receptor

Purity / Grade:

>98%

Solubility:

DMSO : 9.09 mg/mL (25.77 mM; Need ultrasonic); H₂O :

Observed Molecular Weight:

352.75

Product Description


SD-208 is a selective **TGF- β RI (ALK5)** inhibitor with **IC₅₀** of 48 nM, and > 100-fold selectivity over TGF- β RII.

IC₅₀ & Target: IC₅₀: 48 nM (TGF- β RI)

In Vitro: SD-208 inhibits the cell growth and constitutive and TGF-beta-evoked migration and invasion, and enhances immunogenicity in murine SMA-560 and human LN-308 glioma cells^[1]. SD-208 blocks TGF-beta-induced phosphorylation of the

receptor-associated Smads, Smad2 and Smad3, and stimulates epithelial-to-mesenchymal transdifferentiation, migration, and invasiveness into Matrigel in vitro^[2]. SD-208 also abolishes the promoting effect of TGF- β on neointimal smooth muscle-like cell (SMLC) proliferation and migration in vitro^[3].

In Vivo: SD-208 (1 mg/mL, p.o.) significantly prolongs the median survival of SMA-560 glioma-bearing mice^[1]. In syngeneic 129S1 mice, SD-208 (60 mg/kg/d, p.o.) inhibits primary R3T tumor growth, and reduces the number and the size of lung metastases^[2]. In the murine aortic allograft model, SD-208 effectively reduces the formation of intimal hyperplasia of transplant arteriosclerosis (TA)^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!